Indivior resolves antitrust multi-district litigation claims

UK addiction treatment specialist Indivior (LSE/Nasdaq: INDV) saw its shares edge up 3% to 1,812 pence by early afternoon, as it revealed a resolution to the claims brought by the end payor class of litigants in the In re Suboxone Antitrust Litigation multi-district litigation (MDL).

The agreement is subject to initial approval by the US District Court for the Eastern District of Pennsylvania, a notice period, participation by an appropriate number of end payors and final approval of the Court.

As part of the deal, Indivior expects to pay $30 million to the End Payor Claimants. The settlement amount is in line with the current provision of $188 million for the MDL. Once the agreement is approved and entered by the court, the final settlement amount will be recorded against the $188 million provision. Payment into an escrow account for the benefit of the End Payor Claimants is expected to be made in September 2023, and funded from the company's existing cash balance.